var data={"title":"Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Michael Camilleri, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 05, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) of a variety of serum proteins, many of which circulate as constituents of plasma [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. The subunit proteins forming amyloid deposits are derived from soluble precursors which have undergone conformational changes that lead to the adoption of a predominantly antiparallel beta-pleated sheet configuration. These fibrils can be identified on biopsy specimens both by their characteristic appearance on electron microscopy and by their ability to bind Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence). These deposits may result in a wide range of clinical manifestations depending upon their type, location, and the amount of deposition.</p><p>This topic will review the clinical manifestations, diagnosis, and management of gastrointestinal amyloidosis. A general overview of the genetics, pathogenesis, clinical manifestations, diagnosis, and treatment of the different amyloid disorders is discussed in detail, separately. (See <a href=\"topic.htm?path=genetic-factors-in-the-amyloid-diseases\" class=\"medical medical_review\">&quot;Genetic factors in the amyloid diseases&quot;</a> and <a href=\"topic.htm?path=overview-of-amyloidosis\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;</a> and <a href=\"topic.htm?path=renal-amyloidosis\" class=\"medical medical_review\">&quot;Renal amyloidosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of amyloid cardiomyopathy&quot;</a> and <a href=\"topic.htm?path=treatment-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">&quot;Treatment of amyloid cardiomyopathy&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis\" class=\"medical medical_review\">&quot;Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis&quot;</a> and <a href=\"topic.htm?path=dialysis-related-amyloidosis\" class=\"medical medical_review\">&quot;Dialysis-related amyloidosis&quot;</a> and <a href=\"topic.htm?path=musculoskeletal-manifestations-of-amyloidosis\" class=\"medical medical_review\">&quot;Musculoskeletal manifestations of amyloidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H628577004\"><span class=\"h1\">TYPES OF AMYLOID</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several major forms of amyloidosis. Nomenclature for amyloid subunit proteins includes the letter &quot;A,&quot; followed by the abbreviation of the name of the precursor protein [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=overview-of-amyloidosis#H3\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;, section on 'Types of amyloidosis'</a>.)</p><p>The most common causes of systemic amyloid deposition are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>AL amyloid, caused by a plasma cell dyscrasia, is due to deposition of protein derived from immunoglobulin light chain fragments.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>AA amyloidosis is a potential complication of chronic diseases in which there is ongoing or recurring inflammation that results in the production of serum amyloid A, an acute phase reactant, which can form amyloid deposits (eg, chronic degenerative arthropathies, particularly rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, inflammatory bowel disease).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other major forms of amyloid seen clinically include dialysis-related amyloidosis, heritable amyloidosis, age-related systemic amyloidosis, and organ-specific amyloid.</p><p/><p class=\"headingAnchor\" id=\"H1467472912\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyloidosis of the gastrointestinal tract may be limited to the gut or part of systemic involvement. In a retrospective review of 2334 patients with amyloidosis, 76 patients (3 percent) had biopsy-proven amyloid involvement of the gastrointestinal tract of which approximately 80 percent had systemic amyloidosis and 20 percent had amyloidosis of the gastrointestinal tract without evidence of an associated plasma cell dyscrasia or other organ involvement [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The distribution of clinically apparent gastrointestinal involvement varies with the type of amyloidosis [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"abstract_t\">4</a>]. Gastrointestinal disease is present in as many as 60 percent of patients with AA amyloidosis [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"abstract_t\">5</a>]. In contrast, gastrointestinal tract involvement appears to be less common in AL amyloidosis, with biopsy diagnosed disease and clinically apparent disease occurring in 8 and 1 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>]. In autopsy series, 56 to 95 percent of patients with amyloidosis have hepatic involvement [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Hepatic amyloid has been reported in up to 90 percent of patients with AL amyloid and 60 percent of patients with AA amyloid. </p><p>The prevalence of dialysis-related amyloidosis has not been well studied but clinically apparent disease does not appear to be common [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"abstract_t\">9</a>]. Senile amyloidosis is found in 10 to 36 percent of patients over 80 years old and mainly involves the heart, but can also be seen throughout the gastrointestinal tract. Amyloid has been reported in subserosal veins of 41 to 44 percent of older adult patients, mainly in the large and small bowel [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"abstract_t\">10</a>]. </p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal disease in amyloidosis results from either mucosal infiltration or neuromuscular infiltration. In addition, an extrinsic autonomic neuropathy may also affect gut function.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mucosal infiltration</strong> &ndash; The most common sites of mucosal infiltration are the second part of the duodenum (100 percent), the stomach and colorectum (&gt;90 percent), and the esophagus (approximately 70 percent) (<a href=\"image.htm?imageKey=GAST%2F81395%7EGAST%2F73928%7EGAST%2F58003\" class=\"graphic graphic_picture graphicRef81395 graphicRef73928 graphicRef58003 \">picture 1A-C</a>) [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"abstract_t\">11</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In AL amyloidosis, amyloid deposition in the muscularis mucosae, submucosa, and muscularis propria leads to polypoid protrusions and thickening of the valvulae conniventes. As a result, AL amyloidosis usually presents with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In AA amyloidosis, granular amyloid deposition occurs mainly in the mucosa, resulting in the fine granular appearance, mucosal friability, and erosions. As a result, AA amyloidosis presents with diarrhea and malabsorption [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients with dialysis-related amyloid, the development of gastrointestinal amyloidosis is associated with the length of time on dialysis [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"abstract_t\">9</a>]. Vascular deposition can range from subtle hyalinization of the vascular intima and media within submucosal vessels to significant thickening of the vessel wall with resultant mucosal ischemia. Interstitial deposits are usually localized to the mucosa, submucosa, and muscularis propria but can range from immunoreactive beta<sub>2-</sub>microglobulin amyloid without mural expansion to macroscopic nodular deposits (amyloid tumors) within the muscularis propria. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neuromuscular</strong> <strong>infiltration </strong>&ndash; Neuromuscular infiltration has been reported in patients with AL, AA, and dialysis-related amyloid and usually induces stasis syndromes. Neuromuscular infiltration initially affects the intrinsic nervous system and results in a neuropathic process that is characterized by normal amplitude but uncoordinated contractions [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/13,14\" class=\"abstract_t\">13,14</a>]. Tissue wall infiltration results in a myopathic process with low amplitude contractions that are typically associated with significantly prolonged transit (<a href=\"image.htm?imageKey=GAST%2F62577\" class=\"graphic graphic_waveform graphicRef62577 \">waveform 1</a>) [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"abstract_t\">15</a>]. The preferential site of amyloid infiltration varies by the type of amyloidosis [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/16,17\" class=\"abstract_t\">16,17</a>]. In one study that evaluated 16 patients with amyloidosis and intestinal pseudo-obstruction (13 with AA, 2 with AL, and 1 with dialysis-related amyloidosis), extensive infiltration and replacement of the muscularis propria by amyloid deposits throughout the gastrointestinal tract, especially the small intestine, were found in AL and dialysis-related amyloidosis cases. In contrast, in patients with AA amyloidosis, there was amyloid infiltration in the myenteric plexus without appreciable muscle infiltration. </p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H21931579\"><span class=\"h2\">Clinical presentation</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Gastrointestinal tract amyloidosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with symptomatic gastrointestinal amyloidosis usually present with one of four syndromes [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/6,18-23\" class=\"abstract_t\">6,18-23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gastrointestinal bleeding</strong> &ndash; Bleeding is the presenting symptom in 25 to 45 percent of patients with gastrointestinal tract amyloidosis [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Bleeding may be due to ischemia or infarction, vascular friability, or mucosal lesions (ulcers, nodularity or polypoid lesions, erosions, submucosal hematomas, and small mucosal hemorrhages) [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/3,26,27\" class=\"abstract_t\">3,26,27</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Malabsorption </strong>&ndash; Patients with amyloidosis may develop malabsorption due to mucosal infiltration, pancreatic insufficiency or bacterial overgrowth and present with weight loss (median 13.6 kg in one series), diarrhea, or steatorrhea [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/28,29\" class=\"abstract_t\">28,29</a>]. Less common features included anorexia, dizziness, hypotension, or orthostatic changes in blood pressure. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption#H2\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of malabsorption&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Protein-losing gastroenteropathy </strong>&ndash; Patients with protein-losing gastroenteropathy usually present with diarrhea, edema, ascites, pleural or pericardial effusion and have laboratory evidence of hypoalbuminemia [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"abstract_t\">30</a>]. (See <a href=\"topic.htm?path=protein-losing-gastroenteropathy#H2821906469\" class=\"medical medical_review\">&quot;Protein-losing gastroenteropathy&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Chronic gastrointestinal dysmotility </strong>&ndash; Less often, patients may present with constipation, or nausea, vomiting, abdominal pain, bloating, or chronic intestinal pseudo-obstruction [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/13,16\" class=\"abstract_t\">13,16</a>]. Dysmotility can also result in rapid intestinal transit and cause diarrhea [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"abstract_t\">31</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other rare symptoms of amyloidosis include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cholangitis due amyloid deposition at the ampulla of Vater [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Bowel obstruction due to encapsulating peritonitis or extraluminal amyloidoma [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/33,34\" class=\"abstract_t\">33,34</a>].</p><p/><p>While patients with AA amyloidosis usually present with diarrhea and malabsorption, patients with AL amyloidosis usually present with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Hepatic amyloidosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations of hepatic amyloid deposition are usually mild with hepatomegaly and elevated alkaline phosphatase being the most frequent findings [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/35\" class=\"abstract_t\">35</a>]. Patients with hepatic amyloidosis often have concurrent symptoms of fatigue, weight loss, and anorexia due to systemic amyloidosis.</p><p>Hepatomegaly is present in 57 to 83 percent of patients with hepatic amyloidosis and does not correlate with the amount of amyloid deposition [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/7,36\" class=\"abstract_t\">7,36</a>]. While patients may have associated ascites, this is more likely due to concurrent heart failure or hypoalbuminemia. Chronic liver disease and portal hypertension are rare. The most frequently abnormal test of hepatic function is an elevated serum alkaline phosphatase level. In one study that included 98 patients with hepatic amyloidosis, an elevated alkaline phosphatase was noted in 86 percent of patients, of which 61 percent had values of 500 int. <span class=\"nowrap\">units/L</span> or more [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"abstract_t\">37</a>]. The serum aspartate aminotransferase (AST) was more than twice the upper limit of normal in 37 percent of patients.</p><p>Hepatic involvement can be seen in up to 90 percent of patients with AL amyloid and 60 percent of patients with AA amyloidosis [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/7,8,38\" class=\"abstract_t\">7,8,38</a>]. Clinical features of hepatic involvement in AA amyloidosis are similar to those seen in AL amyloidosis. Although histologic differences between AL and AA amyloidosis have been described, there is considerable overlap making the significance of these observations unclear [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/38-40\" class=\"abstract_t\">38-40</a>]. </p><p>Although some case reports have suggested that patients with hepatic amyloidosis have an increased risk of bleeding <span class=\"nowrap\">and/or</span> hepatic rupture following the biopsy, this has not been consistently demonstrated [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"abstract_t\">18</a>]. (See <a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">&quot;Approach to liver biopsy&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H438020436\"><span class=\"h2\">Imaging findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiologic findings of gastrointestinal amyloidosis are nonspecific [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"abstract_t\">41</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gastrointestinal tract amyloidosis </strong>&ndash; On small bowel follow-through and cross sectional imaging with computed tomographic (CT) scan or magnetic resonance imaging (MRI) in patients with AA amyloid, the mucosa may have a coarse mucosal pattern with innumerable fine granular elevations due to expansion of the lamina propria by amyloid deposits [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"abstract_t\">42</a>]. In patients with AL amyloid, findings include polypoid protrusions, thickening of the folds, luminal narrowing, loss of haustrations, thickened mucosal folds, mucosal nodularity, and ulceration. Dilatation of the small bowel or colon may be seen in patients with neuromuscular amyloid infiltration (<a href=\"image.htm?imageKey=GAST%2F77965\" class=\"graphic graphic_diagnosticimage graphicRef77965 \">image 1</a>). Rarely mesenteric thickening or adenopathy may be seen on CT scan [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"abstract_t\">42</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatic amyloidosis </strong>&ndash; Ultrasonographic findings of hepatic amyloidosis include heterogeneous echogenicity [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"abstract_t\">41</a>]. On CT scan, diffuse or focal regions of decreased parenchymal attenuation with or without extensive calcification may be seen. MRI demonstrates significantly increased signal intensity on T1-weighted images of the liver without significantly altered signal intensity on T2-weighted images; the reason for high signal intensity on T1 is unclear.</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal amyloidosis should be suspected in patients with diarrhea, weight loss, or gastrointestinal bleeding and disorders known to be associated with amyloidosis (eg, plasma cell dyscrasia, chronic inflammatory disease, and chronic renal failure on maintenance dialysis). Amyloidosis should also be suspected when there is involvement of other organs characteristic of systemic amyloid deposition (eg, proteinuria, hepatomegaly and elevated alkaline phosphatase, restrictive cardiomyopathy, neuropathy, unexplained edema, carpal tunnel syndrome, unexplained facial or neck purpura, or macroglossia). The diagnosis of gastrointestinal amyloid requires a tissue biopsy with positive staining of amyloid by Congo red or the presence of amyloid fibrils on electron microscopy. (See <a href=\"topic.htm?path=overview-of-amyloidosis#H10\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;, section on 'Clinical manifestations'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tissue biopsy</strong> &ndash; Based on the gastrointestinal symptoms, we perform a colonoscopy <span class=\"nowrap\">and/or</span> an upper endoscopy to obtain rectal or duodenal mucosal biopsies in patients with suspected amyloidosis and to exclude other etiologies. In patients with unexplained hepatomegaly and elevated alkaline phosphatase, a liver biopsy serves to establish the diagnosis of hepatic amyloid and rule out other infiltrative liver diseases. (See <a href=\"#H628576679\" class=\"local\">'Differential diagnosis'</a> below.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Endoscopy</strong> &ndash; The endoscopic appearance of amyloidosis is not specific. The gastrointestinal tract mucosa may have a fine granular appearance, polypoid protrusions, erosions, ulcerations, friability, and thickening of the wall [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/11,43\" class=\"abstract_t\">11,43</a>]. Rarely, patients have tumor-forming deposits of amyloid, called amyloidomas [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/44-46\" class=\"abstract_t\">44-46</a>]. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Histology</strong> &ndash; On hematoxylin and eosin stained biopsy sections, amyloid appears as a pink, amorphous, waxy substance with a characteristic 'cracking' artifact (<a href=\"image.htm?imageKey=GAST%2F81395%7EGAST%2F73928%7EGAST%2F58003\" class=\"graphic graphic_picture graphicRef81395 graphicRef73928 graphicRef58003 \">picture 1A-C</a>). In the gastrointestinal tract, amyloid deposits may be seen in the mucosa and submucosa and are best identified in the wall of blood vessels. In patients with hepatic amyloid, deposits are usually seen periportally in the space of Disse but the deposits are occasionally centrilobular. Atrophy of hepatocytes may be seen due to compression by amyloid fibrils [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent2\">The presence of amyloid fibrils can be confirmed by their characteristic appearance on electron microscopy and by their ability to bind Congo red (leading to green birefringence under polarized light) or thioflavine-T (producing an intense yellow-green fluorescence) [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>]. It is important to note that biopsy sections that are very thin (ie, 6 microns or less) may not stain appropriately with Congo red despite the presence of amyloid fibrils on electron microscopy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Determining the type of amyloid and underlying etiology</strong> &ndash; Once the histologic diagnosis of amyloidosis is made, it is important to determine the type of amyloid and the underlying cause. This evaluation is discussed in detail, separately. (See <a href=\"topic.htm?path=clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis#H1666063\" class=\"medical medical_review\">&quot;Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis&quot;, section on 'Determining the type of amyloid'</a> and <a href=\"topic.htm?path=overview-of-amyloidosis#H156200404\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;, section on 'Histopathology and protein analysis'</a>.). </p><p/><p class=\"headingAnchor\" id=\"H628576679\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of gastrointestinal amyloidosis varies based on the clinical presentation. Other causes of diarrhea with mucosal erosions include inflammatory bowel disease (ulcerative colitis and Crohn disease), radiation colitis, gastrointestinal malignancies, and medication-induced enteropathy. Gastrointestinal tract amyloidosis can be differentiated from these by a history which may be suggestive of the underlying cause and by histology. The differential diagnosis for chronic diarrhea and the evaluation of diarrhea are discussed in detail, separately. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults#H1492761672\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults&quot;, section on 'Differential diagnosis'</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings\" class=\"medical medical_review\">&quot;Approach to the adult with chronic diarrhea in resource-rich settings&quot;</a>.)</p><p>The differential diagnosis of hepatomegaly and elevated alkaline phosphatase includes other infiltrative disorders of the liver including sarcoidosis, tuberculosis, malignancy, and glycogen storage diseases. These can be distinguished from hepatic amyloidosis by liver biopsy. (See <a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests#H19404964\" class=\"medical medical_review\">&quot;Approach to the patient with abnormal liver biochemical and function tests&quot;, section on 'Elevated alkaline phosphatase'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Therapy is directed at the gastrointestinal manifestations and at the underlying cause of amyloidosis.</p><p class=\"headingAnchor\" id=\"H7051724\"><span class=\"h2\">Symptomatic treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with nausea and vomiting or abdominal pain, which is often due to amyloid-related dysmotility, management consists of dietary modification, hydration, and pharmacologic therapy with prokinetics (eg, <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a>, and, where approved, <a href=\"topic.htm?path=domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">domperidone</a>) and antiemetics (eg, <a href=\"topic.htm?path=promethazine-drug-information\" class=\"drug drug_general\">promethazine</a>, <a href=\"topic.htm?path=dimenhydrinate-drug-information\" class=\"drug drug_general\">dimenhydrinate</a>). Small meals consisting of liquid or homogenized foods are better tolerated than solids. Hypercaloric liquid formulations should be used in patients with low caloric intake. Parenteral nutrition may be necessary for patients with severe dysmotility who have failed enteral nutrition together with prokinetics and antiemetic therapy [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=treatment-of-gastroparesis#H81711981\" class=\"medical medical_review\">&quot;Treatment of gastroparesis&quot;, section on 'Prokinetics'</a> and <a href=\"topic.htm?path=chronic-intestinal-pseudo-obstruction#H21\" class=\"medical medical_review\">&quot;Chronic intestinal pseudo-obstruction&quot;, section on 'Prokinetic agents'</a>.)</p><p>In patients with diarrhea and bloating and demonstrated small intestinal bacterial overgrowth, we suggest empiric treatment with antibiotics for small intestinal bacterial overgrowth (eg, quinolones, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>). In case reports, patients with severe diarrhea and hypoalbuminemia due to a protein-losing enteropathy have responded to glucocorticoids and <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/48,49\" class=\"abstract_t\">48,49</a>]. (See <a href=\"topic.htm?path=small-intestinal-bacterial-overgrowth-management#H4\" class=\"medical medical_review\">&quot;Small intestinal bacterial overgrowth: Management&quot;, section on 'Antibiotic therapy'</a> and <a href=\"topic.htm?path=protein-losing-gastroenteropathy#H18\" class=\"medical medical_review\">&quot;Protein-losing gastroenteropathy&quot;, section on 'Management'</a>.)</p><p>The initial management of patients with gastrointestinal bleeding includes triage to the appropriate setting for management (outpatient, inpatient, intensive care unit), general supportive measures (eg, oxygen, establishment of adequate intravenous access), appropriate fluid and blood product resuscitation, and management of coagulopathies, anticoagulants, and antiplatelet agents. In many cases, the bleeding can be controlled with therapies applied at the time of endoscopy or angiography. The management of gastrointestinal bleeding is discussed in detail, separately. (See <a href=\"topic.htm?path=approach-to-acute-lower-gastrointestinal-bleeding-in-adults\" class=\"medical medical_review\">&quot;Approach to acute lower gastrointestinal bleeding in adults&quot;</a> and <a href=\"topic.htm?path=approach-to-acute-upper-gastrointestinal-bleeding-in-adults\" class=\"medical medical_review\">&quot;Approach to acute upper gastrointestinal bleeding in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7051730\"><span class=\"h2\">Treatment of the underlying disorder</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of the underlying disease has been associated with regression of gastrointestinal amyloid (<a href=\"image.htm?imageKey=GAST%2F87769\" class=\"graphic graphic_table graphicRef87769 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/50-54\" class=\"abstract_t\">50-54</a>]. As examples, therapy is aimed at the underlying infectious or inflammatory disorder in secondary AA amyloidosis (eg, anti-TNF therapy in Crohn disease), at the underlying plasma cell dyscrasia in AL amyloidosis, and at either altering the mode of dialysis or considering renal transplantation in patients with dialysis-related amyloidosis. The management of underlying cause of amyloidosis is discussed in detail, separately [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/55-62\" class=\"abstract_t\">55-62</a>]. (See <a href=\"topic.htm?path=overview-of-amyloidosis#H25\" class=\"medical medical_review\">&quot;Overview of amyloidosis&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=treatment-of-aa-secondary-amyloidosis\" class=\"medical medical_review\">&quot;Treatment of AA (secondary) amyloidosis&quot;</a> and <a href=\"topic.htm?path=treatment-and-prognosis-of-immunoglobulin-light-chain-al-amyloidosis-and-light-and-heavy-chain-deposition-diseases\" class=\"medical medical_review\">&quot;Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H628577010\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the gastrointestinal complications can result in significant morbidity, they are not usually the cause of death, which is most often due to renal failure, restrictive cardiomyopathy, or ischemic heart disease. However, the presence of hepatic manifestations has a poor prognosis as it likely reflects relatively severe systemic disease [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/35,63\" class=\"abstract_t\">35,63</a>]. In one series of 98 patients with hepatic amyloidosis, the median survival in patients with hepatic amyloidosis was nine months [<a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"abstract_t\">37</a>]. Independent predictors of shortened survival included heart failure, a total bilirubin &gt;2 <span class=\"nowrap\">mg/dL,</span> and a platelet count <span class=\"nowrap\">&gt;500,000/microL</span>.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Amyloidosis is a generic term that refers to the extracellular tissue deposition of a variety of serum proteins, many of which circulate as constituents of plasma. The most common causes of systemic amyloid deposition are AL amyloid caused by a plasma cell dyscrasia and AA amyloidosis due to ongoing or recurring inflammation from chronic disease. Other major forms of amyloid seen clinically include dialysis-related amyloidosis, heritable amyloidosis, age-related systemic amyloidosis, and organ-specific amyloidosis. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H628577004\" class=\"local\">'Types of amyloid'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal disease in amyloidosis results from either mucosal or neuromuscular infiltration. In addition, an extrinsic autonomic neuropathy may also affect gut function. (See <a href=\"#H2\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with symptomatic gastrointestinal amyloidosis usually present with one of four syndromes: gastrointestinal bleeding, malabsorption, protein-losing gastroenteropathy, and, less often, gastrointestinal dysmotility. While patients with AA amyloidosis usually present with diarrhea and weight loss, patients with AL amyloidosis usually present with constipation, mechanical obstruction, or chronic intestinal pseudo-obstruction.</p><p/><p class=\"bulletIndent1\">Clinical manifestations of hepatic amyloid deposition are usually mild with hepatomegaly and elevated alkaline phosphatase being the most frequent findings. However, patients usually have weight loss, fatigue, and anorexia due to systemic involvement. (See <a href=\"#H21931579\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal amyloidosis should be suspected in patients with diarrhea, weight loss, or gastrointestinal bleeding and disorders known to be associated with amyloidosis (eg, plasma cell dyscrasia, chronic inflammatory disease, and chronic renal failure on maintenance dialysis). Amyloidosis should also be suspected when there is involvement of other organs characteristic of systemic amyloid deposition (eg, proteinuria, hepatomegaly and elevated alkaline phosphatase, restrictive cardiomyopathy, neuropathy, unexplained edema, carpal tunnel syndrome, unexplained facial or neck purpura, or macroglossia). The diagnosis of gastrointestinal amyloid requires a tissue biopsy with positive staining of amyloid by Congo red or the presence of amyloid fibrils on electron microscopy. (See <a href=\"#H11\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although the gastrointestinal complications can result in significant morbidity, they are not usually the cause of death, which is most often due to renal failure, restrictive cardiomyopathy, or ischemic heart disease. However, the presence of hepatic manifestations has a poor prognosis as it likely reflects relatively severe systemic disease. Therapy is directed at the gastrointestinal manifestations and at the underlying cause of amyloidosis. (See <a href=\"#H13\" class=\"local\">'Management'</a> above and <a href=\"#H628577010\" class=\"local\">'Prognosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"nounderline abstract_t\">Nordling E, Abraham-Nordling M. Colonic amyloidosis, computational analysis of the major amyloidogenic species, Serum Amyloid A. Comput Biol Chem 2012; 39:29.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"nounderline abstract_t\">Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med 1980; 302:1283.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"nounderline abstract_t\">Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica 2013; 98:141.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"nounderline abstract_t\">Freudenthaler S, Hegenbart U, Sch&ouml;nland S, et al. Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients. Virchows Arch 2016; 468:569.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"nounderline abstract_t\">Okuda Y, Takasugi K, Oyama T, et al. [Amyloidosis in rheumatoid arthritis--clinical study of 124 histologically proven cases]. Ryumachi 1994; 34:939.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"nounderline abstract_t\">Menke DM, Kyle RA, Fleming CR, et al. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc 1993; 68:763.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"nounderline abstract_t\">LEVINE RA. Amyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patients. Am J Med 1962; 33:349.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/8\" class=\"nounderline abstract_t\">Iwata T, Hoshii Y, Kawano H, et al. Hepatic amyloidosis in Japan: histological and morphometric analysis based on amyloid proteins. Hum Pathol 1995; 26:1148.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"nounderline abstract_t\">Jimenez RE, Price DA, Pinkus GS, et al. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol 1998; 22:729.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"nounderline abstract_t\">Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011; 24:1533.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"nounderline abstract_t\">Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc 1990; 36:10.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"nounderline abstract_t\">Tada S, Iida M, Yao T, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc 1994; 40:45.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"nounderline abstract_t\">Battle WM, Rubin MR, Cohen S, Snape WJ Jr. Gastrointestinal-motility dysfunction in amyloidosis. N Engl J Med 1979; 301:24.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"nounderline abstract_t\">Camilleri M, Malagelada JR, Stanghellini V, et al. Gastrointestinal motility disturbances in patients with orthostatic hypotension. Gastroenterology 1985; 88:1852.</a></li><li class=\"breakAll\">Malagelada JR, Camilleri M, Stanghellini V. Manometric Diagnosis of Gastrointestinal Motility Disorders, Thieme Medical Publishers, New York 1986.</li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"nounderline abstract_t\">Tada S, Iida M, Yao T, et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34:1412.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"nounderline abstract_t\">Tada S, Iida M, Yao T, et al. Gastrointestinal amyloidosis: radiologic features by chemical types. Radiology 1994; 190:37.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"nounderline abstract_t\">Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008; 103:776.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"nounderline abstract_t\">Petre S, Shah IA, Gilani N. Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy. Aliment Pharmacol Ther 2008; 27:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"nounderline abstract_t\">Reddy MB, Poppers DM, Uram-Tuculescu C. Recurrent obscure gastrointestinal bleeding in a patient with gastric amyloid. Clin Gastroenterol Hepatol 2009; 7:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"nounderline abstract_t\">Kim SH, Kang EJ, Park JW, et al. Gastrointestinal amyloidosis presenting with multiple episodes of gastrointestinal bleeding. Cardiovasc Intervent Radiol 2009; 32:577.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"nounderline abstract_t\">Baldewijns M, Ectors N, Verbeeck G, et al. Intermittent subobstruction and cholestasis as complications of duodenal amyloid tumours. Gastroenterol Clin Biol 1995; 19:218.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"nounderline abstract_t\">Hemmer PR, Topazian MD, Gertz MA, Abraham SC. Globular amyloid deposits isolated to the small bowel: a rare association with AL amyloidosis. Am J Surg Pathol 2007; 31:141.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"nounderline abstract_t\">Brandt K, Cathcart ES, Cohen AS. A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med 1968; 44:955.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"nounderline abstract_t\">Levy DJ, Franklin GO, Rosenthal WS. Gastrointestinal bleeding and amyloidosis. Am J Gastroenterol 1982; 77:422.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"nounderline abstract_t\">Chang HS, Myung SJ, Yang SK, et al. Massive small bowel bleeding in a patient with amyloidosis. Gastrointest Endosc 2004; 59:126.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"nounderline abstract_t\">James DG, Zuckerman GR, Sayuk GS, et al. Clinical recognition of Al type amyloidosis of the luminal gastrointestinal tract. Clin Gastroenterol Hepatol 2007; 5:582.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"nounderline abstract_t\">Hayman SR, Lacy MQ, Kyle RA, Gertz MA. Primary systemic amyloidosis: a cause of malabsorption syndrome. Am J Med 2001; 111:535.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"nounderline abstract_t\">Madsen LG, Gimsing P, Schi&oslash;dt FV. Primary (AL) amyloidosis with gastrointestinal involvement. Scand J Gastroenterol 2009; 44:708.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"nounderline abstract_t\">Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintigraphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol 1997; 32:78.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"nounderline abstract_t\">Guirl MJ, H&ouml;genauer C, Santa Ana CA, et al. Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis. Am J Gastroenterol 2003; 98:2219.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"nounderline abstract_t\">Yoshiki Y, Yamamoto G, Takazawa Y, et al. AL amyloidosis with severe gastrointestinal invasion and acute obstructive suppurative cholangitis. Ann Hematol 2012; 91:467.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/33\" class=\"nounderline abstract_t\">Jones J, VanRosendaal G, Cleary C, et al. Primary amyloidosis presenting as small bowel encapsulation. Can J Gastroenterol 2004; 18:169.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"nounderline abstract_t\">Willson TD, Bird J, Azizi R, et al. Extraluminal amyloidoma of the pelvic cavity causing large bowel obstruction. Case Rep Gastroenterol 2011; 5:315.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/35\" class=\"nounderline abstract_t\">Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 1988; 85:73.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/36\" class=\"nounderline abstract_t\">Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54:271.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"nounderline abstract_t\">Park MA, Mueller PS, Kyle RA, et al. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore) 2003; 82:291.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/38\" class=\"nounderline abstract_t\">Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol 1991; 22:904.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"nounderline abstract_t\">Chopra S, Rubinow A, Koff RS, Cohen AS. Hepatic amyloidosis. A histopathologic analysis of primary (AL) and secondary (AA) forms. Am J Pathol 1984; 115:186.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/40\" class=\"nounderline abstract_t\">Looi LM, Sumithran E. Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis. Hum Pathol 1988; 19:732.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"nounderline abstract_t\">Kim SH, Han JK, Lee KH, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol 2003; 58:610.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"nounderline abstract_t\">Araoz PA, Batts KP, MacCarty RL. Amyloidosis of the alimentary canal: radiologic-pathologic correlation of CT findings. Abdom Imaging 2000; 25:38.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"nounderline abstract_t\">Bighi S, Trevisani L, Lupi L, et al. Amyloidosis of the gastric stump: radiographic and CT findings. Gastrointest Radiol 1990; 15:197.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/44\" class=\"nounderline abstract_t\">Kahi CJ, Vakili S, Liepnieks JJ, Benson M. Amyloidoma of the esophagus. Am J Gastroenterol 2007; 102:910.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"nounderline abstract_t\">Saindane AM, Losada M, Macari M. Focal amyloidoma of the small bowel mimicking adenocarcinoma on CT. AJR Am J Roentgenol 2005; 185:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/46\" class=\"nounderline abstract_t\">Peny MO, Debongnie JC, Haot J, Van Gossum A. Localized amyloid tumor in small bowel. Dig Dis Sci 2000; 45:1850.</a></li><li class=\"breakAll\">Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.</li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"nounderline abstract_t\">Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 2005; 12:48.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/49\" class=\"nounderline abstract_t\">Shin JK, Jung YH, Bae MN, et al. Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis. Mod Rheumatol 2013; 23:406.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"nounderline abstract_t\">Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54:2997.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"nounderline abstract_t\">Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009; 28:1113.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/52\" class=\"nounderline abstract_t\">Dainaka K, Isozaki Y, Kunieda K, et al. [A case of gastrointestinal amyloidosis and hypoproteinemia improved by tocilizumab]. Nihon Shokakibyo Gakkai Zasshi 2016; 113:245.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/53\" class=\"nounderline abstract_t\">Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 2010; 29:1195.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/54\" class=\"nounderline abstract_t\">Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int 2008; 28:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/55\" class=\"nounderline abstract_t\">Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis 2014; 9:61.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/56\" class=\"nounderline abstract_t\">Dhodapkar MV, Jagannath S, Vesole D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997; 27:351.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/57\" class=\"nounderline abstract_t\">Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25:465.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/58\" class=\"nounderline abstract_t\">Gertz MA, Lacy MQ, Dispenzieri A, et al. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19:136.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/59\" class=\"nounderline abstract_t\">Suhr OB, Holmgren G, Steen L, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995; 60:933.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/60\" class=\"nounderline abstract_t\">Mejhert M, Hast R, Sandstedt B, Janczewska I. Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract. BMJ Case Rep 2011; 2011.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/61\" class=\"nounderline abstract_t\">Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27:823.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/62\" class=\"nounderline abstract_t\">Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003; 48:2019.</a></li><li><a href=\"https://www.uptodate.com/contents/gastrointestinal-amyloidosis-clinical-manifestations-diagnosis-and-management/abstract/63\" class=\"nounderline abstract_t\">Levy M, Fryd CH, Eliakim M. Intrahepatic obstructive jaundice due to amyloidosis of the liver. A case report and review of the literature. Gastroenterology 1971; 61:234.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2642 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H628577004\" id=\"outline-link-H628577004\">TYPES OF AMYLOID</a></li><li><a href=\"#H1467472912\" id=\"outline-link-H1467472912\">EPIDEMIOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H21931579\" id=\"outline-link-H21931579\">Clinical presentation</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Gastrointestinal tract amyloidosis</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Hepatic amyloidosis</a></li></ul></li><li><a href=\"#H438020436\" id=\"outline-link-H438020436\">Imaging findings</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">DIAGNOSIS</a></li><li><a href=\"#H628576679\" id=\"outline-link-H628576679\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">MANAGEMENT</a><ul><li><a href=\"#H7051724\" id=\"outline-link-H7051724\">Symptomatic treatment</a></li><li><a href=\"#H7051730\" id=\"outline-link-H7051730\">Treatment of the underlying disorder</a></li></ul></li><li><a href=\"#H628577010\" id=\"outline-link-H628577010\">PROGNOSIS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2642|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/77965\" class=\"graphic graphic_diagnosticimage\">- Amyloidosis of small bowel UGI</a></li></ul></li><li><div id=\"GAST/2642|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/81395\" class=\"graphic graphic_picture\">- Duodenal amyloid HandE</a></li><li><a href=\"image.htm?imageKey=GAST/73928\" class=\"graphic graphic_picture\">- Duodenal amyloid Congo red</a></li><li><a href=\"image.htm?imageKey=GAST/58003\" class=\"graphic graphic_picture\">- Amyloid high power HandE</a></li></ul></li><li><div id=\"GAST/2642|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/87769\" class=\"graphic graphic_table\">- Reducing the supply of fibril precursors in systemic amyloidosis</a></li></ul></li><li><div id=\"GAST/2642|Waveform\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"WAVEFORMS\">WAVEFORMS</a></div><ul><li><a href=\"image.htm?imageKey=GAST/62577\" class=\"graphic graphic_waveform\">- Gastrointestinal manometry in amyloidosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-acute-lower-gastrointestinal-bleeding-in-adults\" class=\"medical medical_review\">Approach to acute lower gastrointestinal bleeding in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-acute-upper-gastrointestinal-bleeding-in-adults\" class=\"medical medical_review\">Approach to acute upper gastrointestinal bleeding in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">Approach to liver biopsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings\" class=\"medical medical_review\">Approach to the adult with chronic diarrhea in resource-rich settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests\" class=\"medical medical_review\">Approach to the patient with abnormal liver biochemical and function tests</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-intestinal-pseudo-obstruction\" class=\"medical medical_review\">Chronic intestinal pseudo-obstruction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption\" class=\"medical medical_review\">Clinical features and diagnosis of malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">Clinical manifestations and diagnosis of amyloid cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-ulcerative-colitis-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis\" class=\"medical medical_review\">Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dialysis-related-amyloidosis\" class=\"medical medical_review\">Dialysis-related amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-factors-in-the-amyloid-diseases\" class=\"medical medical_review\">Genetic factors in the amyloid diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=musculoskeletal-manifestations-of-amyloidosis\" class=\"medical medical_review\">Musculoskeletal manifestations of amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-amyloidosis\" class=\"medical medical_review\">Overview of amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=protein-losing-gastroenteropathy\" class=\"medical medical_review\">Protein-losing gastroenteropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-amyloidosis\" class=\"medical medical_review\">Renal amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=small-intestinal-bacterial-overgrowth-management\" class=\"medical medical_review\">Small intestinal bacterial overgrowth: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-immunoglobulin-light-chain-al-amyloidosis-and-light-and-heavy-chain-deposition-diseases\" class=\"medical medical_review\">Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-aa-secondary-amyloidosis\" class=\"medical medical_review\">Treatment of AA (secondary) amyloidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-amyloid-cardiomyopathy\" class=\"medical medical_review\">Treatment of amyloid cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-gastroparesis\" class=\"medical medical_review\">Treatment of gastroparesis</a></li></ul></div></div>","javascript":null}